A Powerful Relationship to Change the Way People Heal
FREDERICK, Md., Oct. 9 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), today announced that Henry Schein, Inc. (NASDAQ:HSIC), the largest provider of healthcare products and services to office-based practitioners in the North American and European markets has agreed to sell and distribute ActiPatch(TM). ActiPatch is a drug-free anti- inflammatory patch.
BioElectronics President Andrew J. Whelan commented on the agreement, saying, "We believe this distribution agreement creates a powerful relationship that will help us realize our vision of changing the way people heal." Mr. Whelan continued, "We recognize Schein's distribution channels will play a critical role in accelerating our expansion and growth. Henry Schein's strong and pervasive relationships in the medical professional community, the extensive reach of its more than 600 U.S. sales representatives, and its proven ability to sell innovative high technology products will greatly expand the scope of our markets and the use of ActiPatch. This agreement is a strong endorsement of our technology and its many potential applications in the medical field." About BioElectronics BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free, anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed electromagnetic therapy for less than a dollar a day. The unique ActiPatch delivery system uses a patented technology to provide a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com/ About Henry Schein
Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The company's four business groups -- Dental, Medical, International and Technology -- serve more than 500,000 customers worldwide, including dental practices and laboratories, physician practices and veterinary clinics, as well as government and other institutions.
Headquartered in Melville, N.Y., Henry Schein employs nearly 11,000 people with operations in 19 countries and sales of $4.6 billion in 2005. For more information, visit the Henry Schein Web site at http://www.henryschein.com/.
Safe Harbor Statement: This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control. DATASOURCE: BioElectronics Corporation CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation, phone: +1-301-644-3906, fax: +1-301-644-3937, Web site: http://www.bioelectronicscorp.com/ http://www.henryschein.com/
|